Kynam Capital Management Portfolio holdings
Kynam Capital Management runs long/short stock funds focused on global healthcare, mainly biotech and the companies developing new therapies. Yue “Derrick” Tang founded the firm in October 2020, is its principal owner and manages its strategies. The funds expect to run a concentrated portfolio with moderate net exposure to the market, based on in-depth research into individual companies. Their investors may include high net worth individuals, pension plans, sovereign wealth funds, endowments and foundations.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$66.3M |
| 2 |
Legend Biotech
LEGN
|
+$38.4M |
| 3 |
Relay Therapeutics
RLAY
|
+$27.2M |
| 4 |
CytomX Therapeutics
CTMX
|
+$25.5M |
| 5 |
Summit Therapeutics
SMMT
|
+$21.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$36.7M |
| 2 |
Apellis Pharmaceuticals
APLS
|
+$33.2M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$28.6M |
| 4 |
Beam Therapeutics
BEAM
|
+$25.4M |
| 5 |
Vera Therapeutics
VERA
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Alector
ALEC
$251M
| $7.66M | 0.42% |
3,808,494
+1,808,494
| +90% | +$3.88M |
2025 Q4
2 quarters
|
|
|
PBLS
27
Parabilis Medicines Inc
PBLS
$3.48B
| $6.84M | 0.38% |
+250,000
| New | +$6.91M |
2026 Q2
0 quarters
|
|
28
Caribou Biosciences
CRBU
$52.5M
| $4.41M | 0.24% |
2,503,302
| – | – |
2023 Q3
11 quarters
|
|
29
ProQR Therapeutics
PRQR
$199M
| $2.91M | 0.16% |
1,566,317
| – | – |
2024 Q4
6 quarters
|
|
30
Candel Therapeutics
CADL
$663M
| $996K | 0.06% |
96,741
-103,259
| -52% | -$780K |
2026 Q1
1 quarter
|
|
31
enGene Therapeutics
ENGN
$106M
| $792K | 0.04% |
457,855
-898,988
| -66% | -$3.67M |
2024 Q3
7 quarters
|
|
32
Traws Pharma
TRAW
$5.53M
| $71.2K | ﹤0.01% |
+84,400
| New | +$116K |
2026 Q2
0 quarters
|
|
|
33
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-825,000
| Closed | -$33.2M | – |
|
34
Biohaven
BHVN
$2.34B
| – | – |
-702,884
| Closed | -$5.95M | – |
|
35
Design Therapeutics
DSGN
$693M
| – | – |
-784,606
| Closed | -$8.35M | – |
|
|
36
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,820,954
| Closed | -$36.7M | – |
|
37
PUT
Revolution Medicines
RVMD
$40.4B
| – | – |
-207,500
| Closed | -$20.2M | – |
|
38
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-560,000
| Closed | -$18.7M | – |
|
39
CALL
Travere Therapeutics
TVTX
$4.79B
| – | – |
-800,000
| Closed | -$23.8M | – |
|
|
40
PUT
Travere Therapeutics
TVTX
$4.79B
| – | – |
-54,900
| Closed | -$1.63M | – |
|
41
Wave Life Sciences
WVE
$718M
| – | – |
-965,193
| Closed | -$7M | – |
|
42
Climb Bio
CLYM
$581M
| – | – |
-1,003,341
| Closed | -$6.87M | – |
|
43
Evommune Inc
EVMN
$229M
| – | – |
-625,496
| Closed | -$14.4M | – |
|
Similar funds
Kynam Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Kynam Capital Management held 43 positions worth $1.81B, up 12% from $1.62B the previous quarter. Its ten largest holdings account for 73% of the portfolio.
Kynam Capital Management's Q2 2026 filing shows 4 new, 12 increased, 7 reduced and 11 closed positions. Its largest new stake was Summit Therapeutics: 1,200,000 shares worth $17.5M. The largest sale was KalVista Pharmaceuticals, an estimated $36.7M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.
- Kynam Capital Management's largest Q2 2026 buy was Summit Therapeutics: 1,200,000 shares worth $17.5M.
- Kynam Capital Management added most to Viridian Therapeutics in Q2 2026, an estimated $66.3M increase.
- Kynam Capital Management's biggest Q2 2026 reduction was BioCryst Pharmaceuticals, cutting an estimated $28.6M.
- Kynam Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.7M.
- Kynam Capital Management's ten largest holdings make up 73% of its $1.81B portfolio in Q2 2026.
- Kynam Capital Management opened 4 new positions and closed 11 in Q2 2026.
- Kynam Capital Management's portfolio value rose 12% quarter-over-quarter to $1.81B.
Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.